Cargando…
Successful treatment with Cinryze® replacement therapy of a pregnant patient with hereditary angioedema: a case report
BACKGROUND: Hereditary angioedema (HAE) is a rare disease characterized with recurrent swelling of subcutaneous or mucosal tissue that resolves in approximately 3 days. It can be presented with peripheral edema, abdominal and life-threatening laryngeal angioedema. A variety of triggers are known to...
Autores principales: | Kardum, Željka, Prus, Višnja, Milas Ahić, Jasminka, Kardum, Darjan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827996/ https://www.ncbi.nlm.nih.gov/pubmed/33485376 http://dx.doi.org/10.1186/s13256-020-02622-3 |
Ejemplares similares
-
Cinryze(™) as the first approved C1 inhibitor in the USA for the treatment of hereditary angioedema: approval, efficacy and safety
por: Lunn, Michael, et al.
Publicado: (2010) -
Human Plasma-Derived, Nanofiltered, C1-Inhibitor Concentrate (Cinryze®), a Novel Therapeutic Alternative for the Management of Hereditary Angioedema Resulting from C1-Inhibitor Deficiency
por: Farkas, Henriette, et al.
Publicado: (2012) -
Erratum to: Human Plasma-Derived, Nanofiltered C1-Inhibitor Concentrate (Cinryze®), a Novel Therapeutic Alternative for the Management of Hereditary Angioedema Resulting From C1-Inhibitor Deficiency
por: Farkas, Henriette, et al.
Publicado: (2012) -
Advances in Hereditary Angioedema: The Prevention of Angioedema Attacks With Subcutaneous C1-Inhibitor Replacement Therapy
por: Lumry, William, et al.
Publicado: (2020) -
SURVIVAL UNTIL DISCHARGE OF VERY-LOW-BIRTH-WEIGHT INFANTS IN TWO CROATIAN PERINATAL CARE REGIONS: A RETROSPECTIVE COHORT STUDY OF TIME AND CAUSE OF DEATH
por: Kardum, Darjan, et al.
Publicado: (2019)